How many units is 2.5 mg of tirzepatide?
Reviewed 8 sourcesPublished by PepVault
2.5 mg has no fixed unit count: it depends on the vial's strength. At 10 mg/mL it is 25 units on a U-100 syringe; at 5 mg/mL, 50. How to read the marks.

- Last reviewed
- Sources
- 8
- Questions
- 7
- Compounds
- 1
The short answer
It depends on how strong the vial is, because a unit measures liquid, not drug. On a U-100 insulin syringe, 100 units fill 1 mL. At 10 mg/mL, 2.5 mg is 25 units (0.25 mL); at 5 mg/mL it is 50 units; at 2.5 mg/mL it is 100 units, a full 1 mL syringe.
Evidence: Syringe and dosing facts come from the FDA label for Zepbound, an FDA safety alert and FDA device records; the unit figures are arithmetic on example vials, and side-effect timing comes from the SURMOUNT-1 phase 3 trial.
Why does 2.5 mg have no fixed number of units?
Milligrams measure tirzepatide. Units measure liquid. On a U-100 insulin syringe, 100 units fill 1 mL, so every unit is one hundredth of a millilitre: 5 units is 0.05 mL and 50 units is 0.5 mL2. The syringe has no idea what is dissolved in it. The only thing that links milligrams to units is the strength of the liquid, in mg per mL, and that is set by how much water went into the vial.
So the same 2.5 mg can be 25 units from one vial and 100 units from another. One line of arithmetic covers every case: units = dose in mg ÷ strength in mg/mL × 100. At 10 mg/mL, 2.5 ÷ 10 × 100 = 25 units, which is 0.25 mL.
Lilly's own tirzepatide shows the same thing. The single-dose Zepbound vial holds 2.5 mg in 0.5 mL, which is 5 mg/mL, so its dose sits on the 0.5 mL line, the 50-unit mark of a U-100 syringe. The multi-dose vial holds 10 mg in 2.4 mL (4.17 mg/mL), so each 2.5 mg dose is 0.6 mL, the 60-unit mark1. Lilly writes these doses in millilitres and asks for a syringe that fits the dose, such as a 1 mL syringe that can measure 0.5 or 0.6 mL1.

Model. Individual results vary.
How many units is 2.5 mg in the common vial sizes?
Here is 2.5 mg worked out for vials and water volumes people commonly use. Every figure comes from the formula above, the same one PepVault's calculator runs, on a U-100 syringe.
| Vial | Water | Strength | 2.5 mg is | Volume | Smallest syringe |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 50 units | 0.5 mL | 0.5 mL |
| 5 mg | 2 mL | 2.5 mg/mL | 100 units | 1 mL | 1 mL, filled to the top |
| 5 mg | 3 mL | 1.67 mg/mL | Over one syringe | 1.5 mL | None: use a stronger mix |
| 10 mg | 1 mL | 10 mg/mL | 25 units | 0.25 mL | 0.3 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 units | 0.5 mL | 0.5 mL |
| 10 mg | 3 mL | 3.33 mg/mL | 75 units | 0.75 mL | 1 mL |
| 15 mg | 1.5 mL | 10 mg/mL | 25 units | 0.25 mL | 0.3 mL |
| 20 mg | 2 mL | 10 mg/mL | 25 units | 0.25 mL | 0.3 mL |
| 30 mg | 3 mL | 10 mg/mL | 25 units | 0.25 mL | 0.3 mL |
| 60 mg | 3 mL | 20 mg/mL | 12.5 units (between whole marks) | 0.125 mL | 0.3 mL |
Two patterns stand out. The strength decides the draw, not the vial size: a 10 mg, 20 mg or 30 mg vial mixed to 10 mg/mL all give 2.5 mg at 25 units. And the water scales the draw in step: the same 10 mg vial gives 25 units with 1 mL, 50 units with 2 mL and 75 units with 3 mL. The number of doses in the vial stays the same either way, four doses of 2.5 mg in a 10 mg vial.
Very weak mixes run off the end of the syringe (a 5 mg vial with 3 mL needs 1.5 mL for one dose), and very strong ones shrink the draw to a few lines that are hard to read. Set the vial, the water and the dose in the calculator below to see where your draw lands, and whether it lands on a clean mark.
Try it
Work out your draw
The calculator the app uses. Put in your vial, your water and your dose, and it shows the units to draw on a U-100 syringe.
Your vial and dose
Example numbersDraw to
40unitson a U-100 syringe
Lands on a numbered mark
- Concentration
- 5 mg/mL5,000 mcg/mL
- Doses per vial
- 5
What do 0.3 mL, 0.5 mL and 1 mL syringes hold?
- 0.3 mL syringe: holds 30 units.
- 0.5 mL syringe: holds 50 units.
- 1 mL syringe: holds 100 units, the full millilitre6.
All three are U-100, so a unit is the same 0.01 mL on each6. What changes is how fine the scale is. In BD's FDA clearance for these syringes, the 0.3 mL and 0.5 mL barrels are marked every unit and the 1 mL barrel every 2 units6. That is why the smallest syringe that holds the whole dose is the easiest to read, and the FDA asks prescribers and compounders to supply a syringe sized for the dose2.
For 2.5 mg that means: 25 units fits a 0.3 mL syringe, where it has a line of its own (on a 1 mL barrel marked every 2 units it falls between two lines, and so does 75); 50 units is more than a 0.3 mL syringe holds and needs a 0.5 mL or 1 mL barrel; 100 units needs a 1 mL syringe, filled to its top line. Some 0.3 mL syringes carry a half-unit scale. FDA's device database lists one, the BD Ultra-Fine 0.3 mL, as a U-100 syringe with half-unit marks3. On a barrel like that, a draw such as 12.5 units has a line of its own instead of falling between two.
How do you read the marks on the barrel?
- Check the barrel or the box says U-100. The formula on this page only works on that scale.
- Find two printed numbers next to each other and count the small lines between them. That tells you what one line is worth on this syringe, because the scale differs between sizes and brands.
- Work out your draw in units first, then find that line before the needle goes into the vial.
- Pull the plunger slightly past the line with the needle tip in the liquid, tap any air bubbles to the top, then push back slowly until the plunger tip reaches the line. That is the method in Lilly's own vial instructions, and the plunger tip is the edge the line is read against1.
Air bubbles matter because they take up space on the scale without holding any drug. A bubble sitting at 25 units means less than 0.25 mL of liquid went in. The full mixing routine, from the water to the stopper, is in our guide to reconstituting tirzepatide.
What changes on a U-40 syringe?
A U-40 syringe is marked for 40 units per mL, not 100. It exists for veterinary insulins: ProZinc holds 40 IU per mL, and its label warns that using any syringe other than a U-40 will give the wrong dose5. FDA's device database lists U-40 syringes such as the BD Pet Syringe, 0.3 mL4. Its unit lines sit at different volumes from a U-100 barrel of the same size.
The volume is what carries the dose, so the count changes with the scale. At 10 mg/mL, 2.5 mg is 0.25 mL: that is 25 units on a U-100 syringe and 10 units on a U-40. The slip runs the other way too. Drawing to the 25 line of a 1 mL U-40 syringe pulls 0.625 mL, which at 10 mg/mL is 6.25 mg, two and a half times the planned dose. A U-100 unit count belongs only on a U-100 barrel.
Which unit mistakes are easiest to make?
The FDA has collected real examples. With compounded semaglutide, another GLP-1 drug sold in vials, it received reports of dosing errors to which confusion between millilitres, milligrams and units may have contributed. In several, patients told to draw 5 units (0.05 mL) on a U-100 syringe drew 50 units, ten times the dose. The FDA also flagged patients given syringes much larger than their dose2. Four checks catch the usual slips:
- mg and mcg: 2.5 mg is 2,500 mcg. A dose typed in the wrong one is off by a factor of 1,000.
- Units and mL: 25 units is 0.25 mL. A dose written as 25 with no unit is the start of most mix-ups, so write the unit every time.
- A new vial is a new strength: if the next vial is a different size or gets a different amount of water, the units change even though the dose did not. Writing the strength on the vial (for example, 10 mg/mL) keeps the math attached to it.
- The scale: U-100 for this math, never U-40.
Why do so many people start at 2.5 mg?
Because it is the label's starting dose. The FDA label for Zepbound starts tirzepatide at 2.5 mg once weekly for 4 weeks, calls that dose a starting step rather than a maintenance dose, and raises it in 2.5 mg steps after at least 4 weeks on each1. Each step changes the draw: at 10 mg/mL, 2.5 mg is 25 units and 5 mg is 50 units. That is the label's schedule, shown here so the arithmetic has real numbers; the dose and its pace are set with a prescriber.
The first weeks and each step up are when the stomach notices most. In SURMOUNT-1, the trial behind Zepbound, the common side effects were gastrointestinal, mostly mild to moderate, and came mainly during dose escalation7. Smaller meals, eating slowly and stopping at the first sign of fullness are simple ways to settle in.
Commonly reported: very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases.
Research-grade tirzepatide vials are not FDA-approved. The FDA notes that unapproved versions are not reviewed for safety, effectiveness and quality before they are sold, and it has warned companies whose products are falsely labelled for research purposes8. The milligrams on such a vial are the seller's figure, and every unit count on this page assumes that figure is right.
Sources
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: prescribing information, Medication Guide and Instructions for Use. Revised 08/2026. DailyMed. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 2024. fda.gov
- U.S. FDA / NLM AccessGUDID. BD Ultra-Fine insulin syringe, U-100, 0.3 mL, 1/2 unit (model 328440, DI 00382908440035). accessgudid.nlm.nih.gov
- U.S. FDA / NLM AccessGUDID. BD Pet Syringes, 0.3 mL x 12 mm, U-40 (model 323000, DI 00382903230006). accessgudid.nlm.nih.gov
- Boehringer Ingelheim Animal Health. PROZINC (protamine zinc recombinant human insulin) 40 IU/mL: package insert. DailyMed. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. 510(k) K190054: BD Insulin Syringe (0.3 mL, 0.5 mL and 1 mL, for U-100 insulin), clearance letter and 510(k) summary. Becton, Dickinson and Company. 2019. accessdata.fda.gov
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. 2026. fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.